GoodRx Holdings, Inc. (NASDAQ: GDRX) Abdiel Capital Management, main shareholder, Llc sells 99,135 shares


The principal shareholder of GoodRx Holdings, Inc. (NASDAQ: GDRX), Abdiel Capital Management, Llc sold 99,135 shares of the company in a transaction that took place on Wednesday, December 15. The shares were sold for an average price of $ 35.97, for a total value of $ 3,565,885.95. The transaction was disclosed in a file with the SEC, which can be accessed through this hyperlink. Large shareholders who own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Abdiel Capital Management, Llc has also recently carried out the following transactions:

  • On Friday, December 17, Abdiel Capital Management, Llc sold 174,144 GoodRx shares. The shares were sold for an average price of $ 34.34, for a total value of $ 5,980,104.96.

GDRX shares traded down $ 0.41 during trading hours on Friday, reaching $ 33.69. 2,225,131 shares of the company were traded, for an average volume of 1,846,376. The stock’s 50-day moving average is $ 41.13 and its 200-day moving average is $ 38.47. The company has a debt to equity ratio of 0.78, a current ratio of 14.47 and a rapid ratio of 14.47. The stock has a market cap of $ 13.44 billion, a price-to-earnings ratio of -47.45, a price-to-earnings-growth ratio of 39.08, and a beta of -0.69. GoodRx Holdings, Inc. has a 52 week low of $ 26.66 and a 52 week high of $ 59.67.

GoodRx (NASDAQ: GDRX) last released its quarterly results on Wednesday, November 10. The company reported earnings per share (EPS) of $ 0.09 for the quarter, beating the consensus estimate of $ 0.01 by $ 0.08. GoodRx recorded a negative return on equity of 31.61% and a negative net margin of 41.36%. In the same quarter of last year, the company made EPS ($ 0.25). Equity research analysts predict that GoodRx Holdings, Inc. will post 0.03 earnings per share for the current fiscal year.

(A d)

It could be the highest grossing event in crypto history. And that only happens once. If you miss it, there is no second chance.

Several institutional investors and hedge funds have recently changed their holdings in the company. Moors & Cabot Inc. acquired a new position in GoodRx shares during the third quarter valued at $ 1,117,000. Kingsview Wealth Management LLC acquired a new position in GoodRx shares during the third quarter valued at $ 230,000. Bank of New York Mellon Corp increased its stake in GoodRx shares by 14.4% during the third quarter. Bank of New York Mellon Corp now owns 39,596 shares of the company valued at $ 1,624,000 after acquiring an additional 4,999 shares during the period. Cetera Advisor Networks LLC acquired a new position in GoodRx shares during the third quarter valued at $ 270,000. Finally, ACT Capital LLC acquired a new position in shares of GoodRx during the third quarter valued at $ 1,641,000. 51.29% of the shares are currently held by institutional investors and hedge funds.

GDRX has been the subject of a number of analyst reports. Credit Suisse Group raised its price target on GoodRx from $ 45 to $ 52.00 and gave the company an “outperformance” rating in a research report on Tuesday, September 14. Jefferies Financial Group launched a cover on GoodRx in a research report on Wednesday, December 1. They issued a “buy” note and a target price of $ 47.00 on the stock. Cowen lowered his price target on GoodRx from $ 44.00 to $ 42.00 and set an “outperform” rating on the stock in a research report published on Tuesday, August 24. Deutsche Bank Aktiengesellschaft lowered its price target on GoodRx from $ 47.00 to $ 44.00 and set a “hold” rating to the stock in a research report published on Monday, November 15. Finally, Barclays raised its price target on GoodRx from $ 45 to $ 47.00 and gave the company an “overweight” rating in a research report published on Thursday, November 11. One stock research analyst rated the stock with a sell rating, three assigned a conservation rating, and nine assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $ 47.77.

GoodRx Company Profile

GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that allow consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with organized and geographically relevant prescription prices, and access to negotiated prices through GoodRx codes which are used to save money on prescriptions across states. -United.

Further reading: What is diluted earnings per share (diluted EPS)?

Insider buys and sells by quarter for GoodRx (NASDAQ: GDRX)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in GoodRx now?

Before you consider GoodRx, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and GoodRx was not on the list.

While GoodRx currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here